FDA approves ISEMBYLD as first muscle-targeted SMA therapy
ISEMBYLD has received FDA approval as the first muscle-targeted therapy for SMA, with a U.S. launch underway.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
FDA approves ISEMBYLD, first muscle-targeted SMA therapy
Scholar Rock’s ISEMBYLD received FDA approval as the first muscle-targeted therapy for SMA, and the U.S. launch is underway with planned global expansion.